VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 18,000 CareDx, Inc. $CDNA

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in CareDx, Inc. (NASDAQ:CDNA) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 18,000 shares of the company’s stock, valued at approximately $352,000.

A number of other large investors also recently modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of CareDx by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 19,624 shares of the company’s stock valued at $348,000 after purchasing an additional 640 shares during the last quarter. Sei Investments Co. increased its position in shares of CareDx by 1.7% in the 1st quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock valued at $851,000 after purchasing an additional 816 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its position in shares of CareDx by 3.9% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock valued at $425,000 after purchasing an additional 900 shares during the last quarter. MCF Advisors LLC increased its position in shares of CareDx by 292.9% in the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock valued at $26,000 after purchasing an additional 996 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of CareDx by 7.2% in the 1st quarter. US Bancorp DE now owns 18,403 shares of the company’s stock valued at $327,000 after purchasing an additional 1,235 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen raised shares of CareDx from a “sell” rating to a “hold” rating in a research report on Monday, October 20th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 target price on shares of CareDx in a research report on Tuesday, September 23rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CareDx in a research report on Friday. Wells Fargo & Company dropped their target price on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Friday, August 8th. Finally, Craig Hallum dropped their target price on shares of CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $25.50.

CareDx Stock Performance

Shares of CareDx stock opened at $14.97 on Friday. CareDx, Inc. has a 1 year low of $10.96 and a 1 year high of $26.37. The company has a market capitalization of $796.85 million, a P/E ratio of 14.68 and a beta of 2.37. The company’s fifty day moving average is $14.08 and its two-hundred day moving average is $15.83.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.28). CareDx had a return on equity of 18.03% and a net margin of 17.97%.The business had revenue of $90.51 million for the quarter, compared to analysts’ expectations of $90.72 million. During the same period in the previous year, the business posted $0.25 earnings per share. The company’s revenue for the quarter was down 6.1% on a year-over-year basis. As a group, equities analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.